Beckman Coulter Genomics, Danvers, Mass, a leading provider of DNA sequencing services, has received accreditation from the College of American Pathologists (CAP).
Furthering a long-standing commitment to delivering state-of-the-art sequencing services and high levels of customer satisfaction, the facility completed a comprehensive on-site inspection as part of CAP’s accreditation program. The CAP laboratory accreditation program involves a process of inspections of clinical lab records and quality control procedures, and assessments of a lab’s staff qualifications, equipment, facilities, safety program, and overall management.
“Beckman Coulter Genomics is proud to achieve accreditation from the College of American Pathologists,” says Tim Anderson, vice president and general manager of genomic services. “CAP accreditation is recognized as the ‘high-water mark’ for laboratory testing. I congratulate the entire team at Beckman Coulter Genomics. This accomplishment underscores our commitment to advancing healthcare for every person and reinforces our determination to deliver the highest standards of excellence.”
Award of this respected accreditation strengthens Beckman Coulter Genomics’ already strong bioinformatics expertise and extensive experience in study design, guidance, and analysis of customers’ crucial clinical samples.
CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The college’s laboratory improvement programs have customers in more than 100 countries, accrediting 7,600 laboratories and providing proficiency testing to 20,000 laboratories worldwide. For additional information, visit CAP.
“CAP accreditation signifies that our lab operates under rigorous quality standards to generate highly accurate and reliable data,” says Stephen Lyle, MD, PhD, laboratory director at Beckman Coulter Genomics. “We are pleased to be able to provide our customers a sequencing service which satisfies the exacting requirements of regulatory authorities and will help the facility more quickly move findings from clinical trials into clinical use.”